Duality of Interest. I.B.H. reports consulting for Abbott, Roche, Hagar, and Vertex Pharmaceuticals and research support from MannKind, Dexcom, and Tandem Diabetes Care. R.W.B. reports that his institution has received funding on his behalf as follows: grant funding, study supplies, and consulting fees from Insulet, Tandem Diabetes Care, and Beta Bionics; grant funding and study supplies from Dexcom; grant funding from Bigfoot Biomedical; study supplies from Medtronic, Ascencia, and Roche; consulting fees and study supplies from Eli Lilly and Novo Nordisk; and consulting fees from embecta, Sequel Med Tech, Vertex Pharmaceuticals, Hagar, Ypsomed, Sanofi, and Zucara Therapeutics. Y.K. reports receiving product support from Tandem Diabetes Care, Insulet, and Abbott and acting on the advisory board for Tandem Diabetes Care, Novo Nordisk, and Vertex Pharmaceuticals. H.K.A. received grant payments for research from the following companies: Boehringer Ingelheim, Abbott Diabetes Care, AbbVie, Covance, Dexcom, Eli Lilly, Madrigal Pharmaceuticals, Medtronic, Novo Nordisk, MannKind, Carmot Therapeutics, Quintiles, Akero Therapeutics, 89bio, Viking Therapeutics, PPD, Zydus, Kowa Pharmaceuticals America, Insulet, and VtV Therapeutics. G.A. has received consulting fees from Dexcom and Insulet. G.A. has received research support to her institution, Northwestern University, from Fractyl Health, Insulet, Tandem Diabetes Care, and Welldoc. T.B. reports participating in the speakers bureau for Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Dexcom; receiving research support from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Roche, Abbott, Tandem Diabetes Care, MannKind, Insulet, Medtronic, AbbVie, VtV Therapeutics, and Biomea Fusion; and acting on advisory boards for Insulet and MannKind. C.J.L. reports research support paid to her institution from Dexcom, Tandem Diabetes Care, Insulet, Novo Nordisk, and Abbott Diabetes Care and consulting fees from Dexcom and Tandem Diabetes Care. K.C. receives research support provided to her institution from Dexcom, Abbott, Medtronic, Eli Lilly, MannKind, and Insulet and receives consulting fees from Dexcom. A.M. reports acting on the scientific advisory board and participating in speaking engagements for MannKind; acting as a clinical trial principal investigator and participating in speaking engagements for Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, and AstraZeneca; participating in speaking engagements for Janssen Pharmaceuticals; acting as a chief clinical principal investigator, acting on the scientific advisory board, and participating in speaking engagements for Medtronic; acting on the scientific advisory board and acting as a principal investigator for AbbVie; and participating in speaking engagements for Intuity Medical. D.P. reports support from Novo Nordisk, Eli Lilly, MannKind, AstraZeneca, and Boehringer Ingelheim. D.W.S. reports consulting for Abbott Diabetes Care and research support to his institution from the National Institute of Diabetes and Digestive and Kidney Diseases, Tandem Diabetes Care, Novo Nordisk, and Abbott Diabetes Care. R.S.W. reports participation in multicenter clinical trials, through her institution, sponsored by Tandem Diabetes Care, Insulet, Diasome, Eli Lilly, and Amgen, and use of DexCom devices obtained at reduced cost for clinical research. B.W.B. reports stock ownership in Aseko (Glytec); consulting for Beta Bionics, Biomea Fusion, Eli Lilly, Medtronic, MannKind, Novo Nordisk, and Sensorics; participating in the speakers bureau of Abbott, Eli Lilly, Medtronic, MannKind, Novo Nordisk, Sanofi, and Xeris; and receiving grant and research support through his employer from Abvance Therapeutics, Abbott, Dexcom, Diasome, Dompé farmaceutici, Insulet, Eli Lilly, MannKind, Medtronic, Novo Nordisk, Sanofi, Senseonics, REMD Biotherapeutics, Xeris, and vTv Therapeutics. O.H. reports research support from Novo Nordisk, Eli Lilly, and MannKind and acting on an advisory board for Abbott Nutrition. M.K. reports participating in clinical trials for the following sponsor companies: 89bio, AbbVie, Akero Therapeutics, Amgen, AstraZeneca, Biolinq, Biomea Fusion, Boehringer Ingelheim, Corcept Therapeutics, Diamyd Medical, Dexcom, Eli Lilly, Endogenex, Fractyl Health, Gilead, Insulet, Ionis Pharmaceuticals, Kowa, MannKind, Medtronic, Novo Nordisk, Pfizer, Reata Pharmaceuticals, Sinocare, Tandem Diabetes Care, vTv Therapeutics, Zucara Therapeutics, and Zydus. M.K. participates in an advisory board for Corcept Therapeutics and a clinical events committee for Capillary Biomedical. C.J. reports consulting, acting on an advisory board for, and speaking on insulin pumps for Medtronic. J.B.B. reports research support from Bayer, Boehringer Ingelheim, Carmot Therapeutics, Corcept Therapeutics, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; consulting fees from Alkahest, Altimmune, Anji Pharmaceuticals, Aqua Medical, AstraZeneca, Boehringer Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Mediflix, Medscape, Medtronic, Mellitus Health, Metsera, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, ReachMD, Stability Health, Tandem Diabetes Care, Terns Pharmaceuticals, and Vertex Pharmaceuticals; and stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. K.R.K. has received consulting fees from Novo Nordisk. K.R.K. has received research-related contracts (paid to the institution) from Bayer, Boehringer Ingelheim, Carmot Therapeutics, Diasome, Eli Lilly, Novo Nordisk, Rhythm Pharmaceuticals, and vTv Therapeutics. G.O. has received research support paid to her institution from Dexcom, Abbott Diabetes Care, Tandem Diabetes Care, Insulet, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.
